Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-12-03 Director's Dealing
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice - P Savage 2 pages 4.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director's Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, specifically for a newly appointed director. This type of document is a report of personal share transactions or interests by company directors. It does not contain financial results, management discussion, or other report types. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on director's interests, confirming this classification.
2025-12-03 English
Final Director's Interest Notice - S Cooper 2 pages 292.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held and interests in contracts, and notes the date the director ceased to be a director. The content is focused on disclosure of personal share transactions and interests of a company director. The document length is short (2305 characters) and it is a formal notice of director's share dealings rather than a financial report or announcement of a meeting or vote. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). Therefore, the correct classification is DIRS.
2025-12-03 English
Final Director's Interest Notice - M Panaccio 2 pages 292.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held and interests in contracts. The document length is 2300 characters, which is relatively short and focused on director shareholdings. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions or holdings by company directors. There is no indication of financial results, management discussion, or other report types. Therefore, the document is best classified as a Director's Dealing (DIRS) filing.
2025-12-03 English
Correction to Notice of General Meeting/Proxy Form 22 pages 784.9KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an ASX announcement dated 3 December 2025, titled 'Correction to Notice of Meeting' for a General Meeting scheduled on 5 January 2026. It provides detailed instructions on meeting attendance, virtual participation, voting procedures, proxy submission, and shareholder engagement. The content focuses on logistical and procedural information related to the upcoming General Meeting, including corrections to the previously released Notice of Meeting. There is no financial data, management discussion, or report content. The document is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation itself but relates to the Notice of Meeting and proxy form. The document is a formal announcement correcting and clarifying details about the meeting and voting process. Therefore, it fits best under the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-02 English
Notification regarding unquoted securities - RNV 15 pages 51.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted options under an employee incentive scheme. It includes specifics such as the number of securities issued, exercise prices, expiry dates, and details of key management personnel receiving securities. The document is a regulatory announcement notifying the market and shareholders about the issuance of new securities, specifically unquoted options, rather than a financial report or earnings release. It does not contain financial statements or management discussion but is a formal notification of securities issuance. This fits the category of Share Issue/Capital Change (SHA) as it relates to new share issues or capital changes.
2025-12-01 English
Notice of General Meeting/Proxy Form 17 pages 440.9KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'Notice of General Meeting Explanatory Memorandum & Proxy Form' and includes detailed information about a shareholder meeting scheduled for January 5, 2026. It contains instructions on voting, proxy appointments, and explanations of resolutions to be voted on, including ratification and approval of share issuances and options. The content is focused on informing shareholders about the meeting agenda and how to participate in voting, rather than reporting financial results or management commentary. There is no financial data or earnings information presented, nor is it a transcript or a regulatory filing of a different nature. This type of document is a proxy solicitation and information statement sent to shareholders to provide information and request votes for the meeting.
2025-12-01 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.